Structure Therapeutics (GPCR) Depreciation & Amortization (CF) (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Depreciation & Amortization (CF) of $576000.0 for Q1 2026, up 110.22% year-over-year from $274000.0 in Q1 2025, and up 39.81% quarter-over-quarter from $412000.0 in Q4 2025.
Structure Therapeutics (GPCR) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Structure Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $576000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 110.22% year-over-year to $576000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 55.42% YoY), while the FY2025 annual figure was $1.3 million, up 33.3% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $576000.0, up from $412000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $576000.0 in Q1 2026, with the low at $59000.0 in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $222000.0 (2024), against an average of $204764.7.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) changed 0.0% in 2023, then surged 290.28% in 2024.
- Structure Therapeutics' Depreciation & Amortization (CF) stood at $72000.0 in 2022, then changed by 0.0% to $72000.0 in 2023, then soared by 290.28% to $281000.0 in 2024, then jumped by 46.62% to $412000.0 in 2025, then soared by 39.81% to $576000.0 in 2026.
- Business Quant data shows GPCR's Depreciation & Amortization (CF) at $576000.0 in Q1 2026, $412000.0 in Q4 2025, and $356000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 551,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 551,000.00 |
| Jun 30, 2026 | 551,000.00 |
| Mar 31, 2026 | 576,000.00 |
| Mar 31, 2026 | 576,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 291,000.00 |
| Jun 30, 2025 | 291,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Sep 30, 2024 | 265,000.00 |
| Jun 30, 2024 | 232,000.00 |
| Jun 30, 2024 | 232,000.00 |
| Mar 31, 2024 | 222,000.00 |
| Mar 31, 2024 | 222,000.00 |